

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ



السلام عليكم ورحمة الله وبركاته



www.shutterstock.com • 188333630


Viral Hepatitis

2

~~HAV.~~

HBV, HCV. HDV HEV
and HGV

22-12-2024




www.shutterstock.com • 1103225852

HEPATITIS B

Prof DR. Waqar Al – Kubaisy

22 Dec.. 2024

HEPATITIS B



- ❑ Hepatitis B (formerly known as "**serum**" hepatitis
- ❑ Hepatitis B is a **global public health threat** and the world's most common **serious** liver infection.
- ❖ It is up to **100 times more** infectious than the **HIV/AIDS virus**.
- ❖ It also is the primary cause of liver cancer (**hepatocellular carcinoma (HCC)**), which is the **second-leading cause of cancer deaths** in the world.
- ❑ However, it can be **prevented** by currently available **safe and effective vaccine**.
- ❑ **Clinically it is** characterized **by variety of outcomes**.
- ❖ Usually, it is an **acute infection**, which may be either
 - **Subclinical** or **Symptomatic**.
- ❑ Roughly **70 %of** an **acute HBV** infection **have symptoms**



❖ Chronic HBV infection.


- around **5%** of **adults**,
- **30 %** of **children**, and roughly
- **95%** of **early childhood** and infants exposed at birth

will not **clear the virus** and will develop a **chronic HBV** infection

- ❖ In approximately **5 to 15 %** of cases, HBV infection **fails**
- ❖ **to resolve** and become **persistent carriers** of the virus
- **Persistent** HBV infection may cause **progressive liver disease** including **chronic active hepatitis** and **HCC**.

- ❑ HBV can form a **dangerous alliance** with **Delta Virus** and
- ❖ produce a **new form** of **virulent hepatitis** which is considered to be a widespread threat for much of the world.

Geographical Distribution



- ❑ Hepatitis B is **a major global** health problem, and
 - **the most serious type of viral hepatitis.**
- ❖ **More than 2 Billion** people WW have evidence **(one out of three people)** of past or current **HBV infection** and
- ❖ Approximately **1.5 million** people become newly infected **each year**
- ❖ Almost **300 million** people are **chronically infected**
- ❖ Approximately **10%** of infected individuals are **diagnosed**
- ❑ Approximately **two people** die **each minute** from hepatitis B
- ❑ **HBV is the leading cause of liver cirrhosis & HCC WW** .
- **Between 5-15 %** of adults, and
- **up to 95 %** of infants infected
- . Among these,
 - 25%, in the long term, develop **serious liver disease**

**with HBV
become carriers**

- ❑ Hepatitis B is Endemic throughout the world, especially in
 - ❖ Tropical & Developing countries & also in some regions of Europe
- ❑ Its prevalence varies from country to country and depends upon
 - ❑ a complex mix of Behavioural, Environmental and Host Factors
 - ❖ Eastern Mediterranean Region **Sixty million** people are infected
 - ❖ South-East Asia Region, **18 million**
 - ❖ Region of the Americas **5 million**
 - ❖ In general it is **lowest** in countries or areas with **high standards** of living.
 - ❖ HBV infection is a global problem, with 66 % of all the world's population living in areas where there are **high levels of infection**
- ❑ Based on **HBsAg carrier rates**, countries categorized into **3 groups**
 - I. **High Endemicity** ($\geq 8\%$),
 - II. **Intermediate** (2-8%), and
 - III. **Low Endemicity** ($< 2\%$).

- ❖ Hepatitis B is **endemic** in China and other parts of Asia
- ❖ In these **regions** most people become infected **in childhood**
- ❖ and **8-10%** of the adult population are chronically infected.
- ❖ In the **Middle East** an estimated **2-5%** of the general population is chronically infected.
- ❖ In Western Europe and North America **<1%** population is infected


In Jordan The national prevalence of HBV is estimated to be around **2.4%** (**2017**) and has declined from **9.9%** (1985) in the pre-vaccination era.

Agent factors

Epidemiological determinants

HBV is highly contagious **has three distinct antigens** stimulating the production of **three** corresponding **Abs**

1. **Surface Ag "Australia Ag" {HBsAg}** surface Abs (**anti-HBs**)
2. **Core Ag {HBcAg}**, core Abs (anti-HBc) and
3. **"e" Ag (HBeAg)**. "e" Abs (anti-HBe).



These Abs and their Ags constitute very **useful markers** of HBV infection
Pts with HBV infection are expected to have **one or more** HBV markers

(b) Reservoir of Infection :

- ❖ **Man** is the **only** reservoir of infection ;either **carriers** or **cases**.
- ❖ continued infection is due to the **large number** of the **carriers**
- ❖ The **Persistent Carrier** state has been **defined** as the **presence** of
- ❖ **HBsAg** (**with or without** concurrent **HBeAg**) for **more than 6 Mths**

(c) Infective Material:

- ❖ Contaminated **blood** is the **main source** of infection,
- ❖ **body secretions** such as **saliva**, **vaginal secretions** and **semen** of infected persons.

(e) Period of Communicability :

- ❖ HBV is present in the **blood** during the
- **incubation period** (for a month before jaundice) & **acute** phase of the disease
- ❖ Period of communicability is usually **several months**
 - ❖ {occasionally **years** in chronic carriers) or
- ❑ **until disappearance** of **HBsAg** and appearance of surface Abs

d) Resistance :

❑ HBV is quite stable and **capable** of surviving for at **least 7 days** on environmental' surfaces. It is an important occupational hazard for HCWs

- ❖ It can be **readily destroyed** by **sodium hypochlorite**,
- ❖ by heat sterilization in an **autoclave** for **30 -60** minutes

(a)AGE : Host factors

❑ The outcomes of **HBV infection** are **age dependent**.

❑ **Acute HBV** occurs in approximately

➤ **1 %of** perinatal,

➤ **10 %of** early childhood (1-5 years of age) and

➤ **30 %of** late (> 5 years age) HBV infections.


❖ **Mortality** from fulminant HB is approximately **70 %**

❑ The development of **Chronic HBV** infection is **inversely** related to **age** and occurs in approximately

✓ **95 %** of persons infected **perinatally**,

✓ in **30 %** infected in **childhood** (<6 years of age)

✓ in **5 %** infected **a≥ 6 years** of age



(b) High-risk Groups :

❑ Certain groups carry higher risks.

❖ Health care workers and Laboratory personnel

Annual **incidence** of HBV infection in **surgeons** is estimated to be **50 times greater** than that in the general **population**, and **more** than **twice** that of other **physicians**.

❖ Recipients of **blood** transfusions,

❖ **Homosexuals**, Prostitutes, Percutaneous **drug abusers**,

❖ **Infants** of **HBV carrier** mothers,

❖ Recipients of **solid organ** transplants and

❖ **Immunocompromised** Patients

❖ **Hepatitis B and HIV** Infection: About **1%** HBV

❖ pts (2.7 million) are also infected with HIV.

➤ HIV markedly **increases the risk** of developing HBV-associated liver cirrhosis & HCC mortality rate increases among HIV-+ve due to HBV co infection

Serological screening & vaccination of high-risk groups is **highly** recommended



DIAGNOSIS

- ❖ *These Abs and their Ags constitute very useful markers of HBV infection.*
- ❖ *Pts with HBV infection are expected to have one or more HBV markers.*

They can be used to distinguish **acute** and **chronic** infections.

- ❖ Laboratory diagnosis of HBV infection **focuses on the**
- ❖ **detection of the (HBs Ag).**

Acute HBV infection

is characterized by the presence of **HBsAg** and **IgM** antibody to the, **HBcAg**. During the **initial phase** of infection, patients are also **seropositive** for **HBeAg**.

- ❖ **HBeAg** is a marker of **high levels of replication** of the virus.
- ❖ The presence of **HBeAg** indicates that the patient's blood and body fluids are **HIGHLY INFECTIOUS**.

Chronic infection is characterized by the

- persistence of **HBsAg** for at least **6 months** (with or without HBeAg).
- Persistence of **HBs Ag** is the principal marker of risk for
- Developing **chronic liver** disease and **liver cancer** (HCC) later in life.


There are three distinct antigen antibody systems that relate to HBV infection and a variety of circulating makers that are useful in diagnosis. Interpretation of common serological patterns is as shown in Table below

Common serologic patterns in hepatitis B virus infection and their interpretation

HBsAg	Anti-HBs	Anti-HBc	HBeAg	Anti-HBe	Interpretation
+	-	IgM	+	-	Acute hepatitis B
+	-	IgG ¹	+	-	Chronic hepatitis B with active viral replication
+	-	IgG	-	+	Chronic hepatitis B with low viral replication
+	+	IgG	+ or -	+ or -	Chronic hepatitis B with heterotypic anti-HBs (about 10% of cases)
-	-	IgM	+ or -	-	Acute hepatitis B
-	+	IgG	-	+ or -	Recovery from hepatitis B (immunity)
-	+	-	-	-	Vaccination (immunity)
-	-	IgG	-	-	False-positive, less commonly, infection in remote past

Low levels of IgM anti-HBc may also be detected.

Modes Of Transmission



a. *Parenteral route*

- ❖ Hepatitis B is a blood-borne infection.
- It is transmitted by infected BI and BI. Products, through *transfusions, dialysis, contaminated syringes and needles pricks of skin, handling of infected blood, accidental inoculation of minute quantities of blood such as during surgical and dental procedures, immunization, tattooing, ear piercing, nose piercing, circumcision, acupuncture, etc .*
- ❖ also occur through the reuse of needles and syringes particularly among persons who inject drugs
- Accidental percutaneous inoculations by shared razors & tooth brushes

➤ b. Perinatal transmission

- ❖ Spread of infection from HBV carrier mothers to their babies
- ❑ In highly endemic areas,
- ❖ HBV is most commonly spread from mother to child at birth (**perinatal transmission**), or through **horizontal transmission** especially from an

- ❑ through **horizontal transmission** especially from an infected child to an uninfected child during the first 5 years of life.
- ❖ The development of **chronic infection** is very common in
- ❖ **infants infected** from their mothers **or** before the age **of 5 years** appears to be **an important factor for the high prevalence** of **HBV infection in some regions**, particularly China and Southeast Asia
 - ❑ **Majority** of children **born to HBeAg+Ve mothers** become **chronically** infected.

The mechanism of perinatal infection is uncertain.


Although HBV can infect the foetus **in utero**, this rarely happens

- ❖ **and most infections** appear to occur **at birth**, as a result of a
 - **leak** of maternal **blood into** the baby's circulation, or
 - **ingestion** or **accidental inoculation of blood** .
- ❑ Infection of the baby is usually **anicteric** and is recognized by
 - The appearance of **surface antigen(HBsAg)** between
 - **60-120 days** after birth

C. Sexual transmission

❖ ample evidence for the spread of infection by **sexual route**. particularly **male homosexuals**, are at very high risk of infection with HBV.

➤ **Heterosexual** persons with **multiple sex partners** or
 ✓ contact with **sex workers**



d. Other routes

❖ **horizontal transmission**: Transmission from **child-to-child**, is responsible for a majority of HBV infections and carriers in parts of the world other than Asia.

❖ In addition, infection can occur during **medical, surgical and dental procedures, tattooing**, or through the use of razors and similar objects that are contaminated with infected blood.

❑ HBV is an **important occupational** hazard for HCWs

❑ In short, transmission occurs in a wide **variety of epidemiological settings**. **It can spread** either from **carriers** or during **the incubation period**, illness or early **convalescence**.

Who is at risk for chronic disease?

- ❑ The probability of HBV to become chronic depends upon **the age at** which a person becomes infected.
- ❖ **Children <6** years of age who become HBV infected are the most likely to **develop chronic infections.**

In infants and children:

- ❖ **80–95%** of infants infected during **the first year of life** develop chronic HBV
- ❖ **30–50%** of children infected **before the age of 6 years** develop chronic HBV

In adults:

- ❖ **<5%** who are infected as **adults** will **develop chronic infection and**
- ❑ **20–30%** of **chronically infected adults** will develop **cirrhosis and/or liver cancer**

Prevention and Containment



- **SINCE THERE IS NO SPECIFIC TREATMENT,**
- Prevention has been the major aim in managing HBV.
- ❑ HBV is **preventable** with currently available **safe & effective vaccines**.
- ❑ The following measures are available : .

a. Hepatitis B Vaccine

- ✓ The recombinant hepatitis B vaccine was introduced in **1986**.
- ✓ The **active** substance in hepatitis B vaccine is **HBsAg**
- ✓ The vaccine is **95% effective** in preventing infection and
- ✓ prevent the development of **chronic disease** and **HCC** due to HBV.
- ❖ **Adults** dose of **10-20 micrograms** initially and again at **1 and 6 months**. (0, 1, 6 month)
- ❖ **Children** age **<10** years **half of the adult** dose at the **same time intervals**. ** **Deltoid muscle** is preferred for injection
- ❖ **For infants & children under 2 years**, **anterolateral aspect of thigh** is used.

❑ HB vaccine **does not interfere** with immune response to any other vaccine & vice-versa.

❑ **The birth** dose of HB vaccine can be **given safely** together with BCG

▪ However, the vaccines should be **given at different sites**

❑ **The recommended schedule for vaccination categorized into those**
Schedules with a birth-dose

In countries with a **high perinatal HBV infection**, **specifically** where the **prevalence of chronic HBV** infection in the **general population is >8%**

First dose of HB vaccine should be given **within 24 hrs** after birth to prevent perinatal

❑ **WHO** recommends that **all infants should** receive their **first dose** of vaccine as soon as **possible after birth**, preferably **within 24 hours**. **Birth (first) dose** and followed by

▪ **2nd , 3rd or 4th doses** to complete the primary series.

▪ usually given with other routine infant vaccines

minimum recommended interval 



- ❖ minimum recommended interval between the doses
- ❖ is **four weeks**
- ❑ **WHO does not** recommend a booster dose of HB vaccine.
- ❑ Protection lasts at **least 20 years**, and is possibly **life-long**
- ❑ The **low incidence** of chronic HBV infection in **children under**
- ❑ **5 years** of age at present can be attributed to the widespread use of **HB vaccine**
- low or intermediate endemicity.** (*Immunization in adults*)
- ❑ In those settings Routine **pre-exposure** vaccination should be
- ❖ considered for groups of adults **high-risk groups** They include:
 - People who frequently **require blood or blood products, dialysis patients, recipients of solid organ transplantations;**
 - **People in prisons; who inject drugs;**
 - household and sexual **contacts of people with chronic HBV infection;** People with **multiple sexual partners**
 - **Healthcare workers** and others who may be exposed to blood and blood products through their work; and **travellers who**

- **Healthcare workers** and others who may be exposed to blood and blood products through their work; and
- **travellers** who **have not completed** their HB vaccination series, before leaving for endemic areas



- ❖ All children and adolescents younger than 18 years-old and
- ❖ **not previously vaccinated should receive the vaccine** if they live in countries where there **is low or intermediate endemicity**

Hepatitis B immunoglobulin (HBIG)

- ❖ For immediate protection, HBIG is used for those acutely
- ❖ **exposed to HBsAg-positive** blood, for example
 - (a) **surgeons**, nurses or laboratory workers
 - (b) **New born infants** of carrier mothers
 - (c) **sexual contacts** of acute hepatitis B patients, and
 - (d) **patients who need protection against HBV infection after liver transplantation.**
- ❖ The **HBIG** should be given **as soon as possible** after an accidental **inoculation** (ideally within 6 hours and preferably not later than 48 hours)

At the same time the victim's blood is drawn for HBsAg testing

Cont. ...Hepatitis B immunoglobulin (HBIG)

- ❖ At the same time the victim's blood is drawn for HBsAg testing.
 - If the test is negative, **vaccination should be started immediately** and a full course given.
 - ❖ If the test is positive no further action is needed
 - ❑ Recommended dose is **0.05 to 0.07 ml/kg of body weight**.
 - ❖ **Two doses** should be given **30 days apart**.
 - ❖ HBIG provides short-term passive protection **approximately 3 months**.
- Passive-active immunization
- The administration of HBIG and HB vaccine is more **efficacious than HBIG** alone.
 - HBIG does not interfere with the antibody response to the HB vaccine
 - ❖ This **combined procedure is ideal**, both for
 - ❖ prophylaxis of persons accidentally exposed to blood known to contain HBV , and
 - prevention of the carrier state in the **new-born** babies of carrier mothers.

HBIG (0.05-0.07 ml/kg)

d. Other Measures

- ❖ screening of all **donated blood** and blood components,
- ❖ and those **positive** for **HBsAg** should be **rejected**.
- ❖ Voluntary blood donation should be **encouraged** because purchased blood has shown a higher risk of post-transfusion hepatitis .
- ❖ **Safe injection** practices,
 - ❖ Furthermore, **safer sex** practices, including **minimizing the number** of partners and **using barrier** protective measures
- ❖ **Health personnel** should be alerted to the **importance of adequate sterilization** of all instruments and to the practice of simple hygienic measures.
- ❖ HB Carriers should be told **not to share razors** or **tooth brushes** and use **barrier methods of contraception**; **they should not donate blood**

Thank You